HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection

Prithwish Ghosh; Vandana Nehra; Zelalem Temesgen

doi:10.1358/dof.2022.47.8.3440035

HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection

Prithwish Ghosh, Vandana Nehra, Zelalem Temesgen

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

Furaprevir (previously TG-2349) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It has shown potent antiviral activity in studies to date and has been safe and well tolerated. It is undergoing evaluation in several phase II and III clinical trials, including in combination with ribavirin and yimitasvir (an NS5a inhibitor).

Original language	English (US)
Pages (from-to)	557-565
Number of pages	9
Journal	Drugs of the Future
Volume	47
Issue number	8
DOIs	https://doi.org/10.1358/dof.2022.47.8.3440035
State	Published - Aug 2022

Keywords

Furaprevir
HCV NS3/4A
Hepatitis C virus
TG-2349

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2022.47.8.3440035

Cite this

@article{d5b78f53c77b48dd88849bdfb4750b23,

title = "HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection",

abstract = "Furaprevir (previously TG-2349) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It has shown potent antiviral activity in studies to date and has been safe and well tolerated. It is undergoing evaluation in several phase II and III clinical trials, including in combination with ribavirin and yimitasvir (an NS5a inhibitor).",

keywords = "Furaprevir, HCV NS3/4A, Hepatitis C virus, TG-2349",

author = "Prithwish Ghosh and Vandana Nehra and Zelalem Temesgen",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Clarivate.",

year = "2022",

month = aug,

doi = "10.1358/dof.2022.47.8.3440035",

language = "English (US)",

volume = "47",

pages = "557--565",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "8",

}

TY - JOUR

T1 - HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection

AU - Ghosh, Prithwish

AU - Nehra, Vandana

AU - Temesgen, Zelalem

PY - 2022/8

Y1 - 2022/8

N2 - Furaprevir (previously TG-2349) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It has shown potent antiviral activity in studies to date and has been safe and well tolerated. It is undergoing evaluation in several phase II and III clinical trials, including in combination with ribavirin and yimitasvir (an NS5a inhibitor).

AB - Furaprevir (previously TG-2349) is a selective inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It has shown potent antiviral activity in studies to date and has been safe and well tolerated. It is undergoing evaluation in several phase II and III clinical trials, including in combination with ribavirin and yimitasvir (an NS5a inhibitor).

KW - Furaprevir

KW - HCV NS3/4A

KW - Hepatitis C virus

KW - TG-2349

UR - http://www.scopus.com/inward/record.url?scp=85139665976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139665976&partnerID=8YFLogxK

U2 - 10.1358/dof.2022.47.8.3440035

DO - 10.1358/dof.2022.47.8.3440035

M3 - Article

AN - SCOPUS:85139665976

SN - 0377-8282

VL - 47

SP - 557

EP - 565

JO - Drugs of the Future

JF - Drugs of the Future

IS - 8

ER -

HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this